Skip to main content
SpringerLink
Log in

Strategies for the Management of Diabetic Dyslipidaemia

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Atherosclerosis, the complication most prominently associated with type 2 diabetes and cardiovascular disease, represents a major burden for both individuals and society. Mortality rates associated with cardiovascular disease among patients with type 2 diabetes are at least 3 times those in the general population, and although ’traditional’ cardiovascular risk factors affect patients with this disorder as they do other individuals, they do not account for the excess risk attached to type 2 diabetes. There is a growing body of evidence to show that hyperglycaemia and dyslipidaemia are connected with this excess cardiovascular risk: hypertriglyceridaemia has been implicated in several prospective clinical studies, and available data suggest that low density lipoprotein (LDL)-cholesterol is more atherogenic in patients with type 2 diabetes than in other individuals. It is possible that this increased atherogenicity is associated with a preponderance of small, dense LDL particles that are more prone to oxidation and glycation than larger fractions and that may be involved in endothelial dysfunction. These findings lead to the recommendation of mandatory global risk assessment, accompanied by good glycaemic control, aggressive lowering of serum levels of LDL-cholesterol and maintenance of serum levels of triglyceride at the lowest possible level in patients with type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1987; 3: 463–524

    Article  PubMed  Google Scholar 

  2. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44

    Article  PubMed  CAS  Google Scholar 

  3. Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993; 21: 920–5

    Article  PubMed  CAS  Google Scholar 

  4. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early mortality and morbidity after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 1992; 85: 1254–64

    Article  PubMed  CAS  Google Scholar 

  5. Orlander PR, Goff DC, Morrissey M, et al. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. Diabetes 1994; 43: 897–902

    Article  PubMed  CAS  Google Scholar 

  6. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91: 979–89

    Article  PubMed  CAS  Google Scholar 

  7. Vigorito C, Betocchi S, Bonzani G, et al. Severity of coronary artery disease in patients with diabetes mellitus: angiographic study of 34 diabetic and 120 nondiabetic patients. Am Heart J 1980: 100 (6 Pt 1): 782–7

    Article  PubMed  CAS  Google Scholar 

  8. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21: 69–75

    Article  PubMed  CAS  Google Scholar 

  9. IDF Task Force on Diabetes Health Economics. Costing Diabetes: the cost of prevention. Brussels: International Diabetes Federation, 1997

    Google Scholar 

  10. Syvänne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 350 Suppl. 1: S120–3

    Google Scholar 

  11. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996; 7: 167–71

    Article  PubMed  CAS  Google Scholar 

  12. James RW, Pometta D. The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 246–52

    Article  PubMed  CAS  Google Scholar 

  13. Howard BJ. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613–28

    PubMed  CAS  Google Scholar 

  14. Taskinen M-R. Hyperlipidaemia in diabetes. Clin Endocrinol Metab 1990; 4: 743–75

    CAS  Google Scholar 

  15. Gibbons GF. Hyperlipidaemia of diabetes. Clin Sci 1986; 71: 477–86

    PubMed  CAS  Google Scholar 

  16. Taskinen M-R. Triglyceride is the major atherogenic lipid in NIDDM. Diabetes Metab Rev 1997; 13: 93–8

    Article  PubMed  CAS  Google Scholar 

  17. Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300–4

    Article  PubMed  CAS  Google Scholar 

  18. Laakso M, Lehto S, Penttilä I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88: 1421–30

    Article  PubMed  CAS  Google Scholar 

  19. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577–83

    Article  PubMed  CAS  Google Scholar 

  20. Lehto S, Rönnemaa T, Haffner SM, et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 48: 1354–9

    Article  Google Scholar 

  21. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–8

    Article  PubMed  CAS  Google Scholar 

  22. Taylor R, Agius L. The biochemistry of diabetes. Biochem J 1988; 250: 625–40

    PubMed  CAS  Google Scholar 

  23. Brownlee M, Vlassara H, Cerami A. Non-enzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101: 527–37

    PubMed  CAS  Google Scholar 

  24. De Graaf J, Hak-Lemmers HLM, Hectors MPC, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11: 298–306

    Article  PubMed  Google Scholar 

  25. Mäkimattila S, Liu M-I, Vakkilainen J, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes: relation to LDL size, oxidized LDL and antioxidants. Diabetes Care 1999; 22: 973–81

    Article  PubMed  Google Scholar 

  26. Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614–20

    Article  PubMed  Google Scholar 

  27. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998; 98: 2513–9

    Article  PubMed  CAS  Google Scholar 

  28. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999; 22 Suppl. 1: 56–9

    Article  Google Scholar 

  29. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721–49

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Helsinki, 00290, Helsinki, Finland

    Marja-Riitta Taskinen (Professor of Medicine)

Authors
  1. Marja-Riitta Taskinen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marja-Riitta Taskinen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taskinen, MR. Strategies for the Management of Diabetic Dyslipidaemia. Drugs 58 (Suppl 1), 47–51 (1999). https://doi.org/10.2165/00003495-199958001-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958001-00011

Keywords

Search

Navigation